AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Please cancel claim 2, and 12 to 24, without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claim 1 (currently amended): A method of treating an active case of multiple sclerosis (MS), comprising administering to an individual in need thereof a pharmaceutically-effective amount ~~amounts~~ of cpn10 and IFN-β, wherein ~~the amounts of cpn10 and IFN-β are suboptimal when administered alone and wherein~~ the therapeutic effect of administering cpn10 and IFN-β together is ~~greater than~~ improved (synergistic) as compared to the therapeutic effect ~~that~~ of administering the same or an equivalent ~~the suboptimal~~ amount of cpn10 or IFN-β alone.

Claim 2 (canceled)

Claim 3 (currently amended): The method of claim 1, wherein IFN-β and cpn10 are administered together in the same formulation.

Claim 4 (currently amended): The method of claim 1, wherein IFN-β and cpn10 are administered separately in different formulations.

Claim 5 (currently amended): The method of claim 1 **[[3]]**, wherein the IFN-β and the cpn10, or, the IFN-β or the cpn10, are administered by injection.

Claim 6 (currently amended): The method of claim 1 **[[4]]**, wherein the IFN-β and the cpn10, or, the IFN-β or the cpn10, is administered orally.

Claim 7 (currently amended): The method of claim 5 [[4]], wherein only the IFN-β is administered by injection.

Claim 8 (currently amended): The method of claim 1, wherein the pharmaceutically effective amount of cpn10 ~~and IFN-β~~ comprises about 5-60 mg of cpn10.

Claim 9 (currently amended): The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 ~~and IFN-β~~ comprises about 10-30 mg of cpn10.

Claim 10 (currently amended): The method of claim 1, wherein the pharmaceutically-effective amount of ~~cpn10 and~~ IFN-β comprises about 1-10 Million International Units (MIU) of IFN-β.

Claim 11 (currently amended): The method of claim 10, wherein the pharmaceutically-effective amount of ~~cpn10 and~~ IFN-β comprises about 4-6 MIU of IFN-β.

Claims 12 to 24 (canceled)

Claim 25 (currently amended): A method of treating multiple sclerosis (MS) in an individual taken off IFN-β treatment or having reduced dose IFN-β treatment because of IFN-β-induced side effects, comprising administering to an individual in need thereof a combination treatment comprising pharmaceutically-effective amounts of cpn10 and IFN-β, wherein ~~the therapeutic effect of administering cpn10 and IFN-β is greater than that of administering an equivalent amount of cpn10 or IFN-β alone~~ the IFN-β is administered at a dose below that which produces clinically significant IFN-β–induced side effects in the individual ~~with respect to delaying relapse of MS~~.

Claim 26 (new): A method for delaying relapse to an active from an inactive state of multiple sclerosis (MS), comprising

(a) providing a pharmaceutical composition comprising cpn10 and IFN-β, or providing two pharmaceutical compositions each comprising cpn10 or IFN-β; and

(b) administering to an individual in need thereof a pharmaceutically-effective amount of cpn10 and IFN-β.

Claim 27 (new): The method of claim 1, claim 25, or claim 26, wherein the cpn10 and IFN-β, or, cpn10 or IFN-β, are administered in a pharmaceutical composition comprising a pharmaceutically-acceptable carrier or a diluent.

Claim 28 (new): The method of claim 27, wherein the cpn10 and IFN-β, or, cpn10 or IFN-β, are provided in a separate container.

Claim 29 (new): The method of claim 27, wherein the cpn10 and IFN-β, or, cpn10 or IFN-β, are provided initially in a dehydrated form, which before administration, are rehydrated by a pharmaceutically-acceptable carrier or diluent.

Claim 30 (new): The method of claim 27, wherein the cpn10 and IFN-β, or, cpn10 or IFN-β, are provided administered in a tablet or a capsule form.

Claim 31 (new): The method of claim 1 or claim 26, wherein the IFN-β is administered at a dose below that which produces clinically significant IFN-β–induced side effects in the individual.

Claim 32 (new): A method for treating multiple sclerosis (MS), comprising

(a) providing a pharmaceutical composition comprising cpn10 and IFN-β, or providing two pharmaceutical compositions each comprising cpn10 or IFN-β; and

(b) administering to an individual in need thereof a pharmaceutically-effective amount of cpn10 and IFN-β,

wherein the IFN-β is administered at a dose below that which produces clinically significant IFN-β–induced side effects in the individual.

Claim 33 (new): The method of claim 1, claim 26 or claim 32, wherein the pharmaceutically effective amount of cpn10 comprises the equivalent of administering about 5 to 60 mg of cpn10 to a 70 kg individual.

Claim 34 (new): The method of claim 33, wherein the pharmaceutically effective amount of cpn10 comprises the equivalent of administering about 10 to 30 mg of cpn10 to a 70 kg individual.

Claim 35 (new): The method of claim 1, claim 26 or claim 32, wherein the pharmaceutically effective amount of IFN-β comprises the equivalent of administering about 1 to 10 Million International Units (MIU) of IFN-β.

Claim 36 (new): The method of claim 35, wherein the pharmaceutically effective amount of IFN-β comprises the equivalent of administering about 4 to 6 Million International Units (MIU) of IFN-β.